RGEN Repligendata gap · 80% coverage
Health Care · Biotechnology · close $175.42 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Repligen (RGEN) has a ThetaGrade House Rating of 53/100 (grade C), ranking #62 of 150 in Health Care. Its strongest pillars are balance sheet (71) and profitability (68); its weakest is valuation (12). Data gap: 3 factors without usable data, so 80% of the method weight is covered. TTM revenue growth is 16.5% and operating margin 8.2%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 80% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 55| Revenue growth YoY (TTM) (22.2%) | 16.5% | 67 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -2.9% | 31 |
Profitability
weight 18.5% (→20.0%) · 68| Operating margin (10.7%) | 8.2% | 40 |
| 4Q gross-margin change (9.3%) | 8.9% | 99 |
Balance sheet
weight 18.5% (→20.0%) · 71| Net debt / EBITDA (10.7%) | -0.39× | 75 |
| Current ratio (5.3%) | 9.05 | 89 |
| Interest coverage (4.0%) | 3.00× | 34 |
Cash flow
weight 12.33% (→13.3%) · 42| FCF margin (6.7%) | 12.7% | 51 |
| FCF yield (6.7%) | 0.9% | 33 |
Valuation
weight 12.33% (→13.3%) · 12| P/E (inverted) (6.7%) | 237.05× | 4 |
| EV/Sales (inverted) (6.7%) | 12.54× | 20 |
Technicals (EOD)
| RSI(14) | 48.8 |
| EMA 9 / 21 | 177.27 / 177.70 |
| 200-day SMA | 144.13 |
| Volume vs 20d avg | 0.89× |
| 20-day return | -1.6% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerIncludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like RGEN's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is RGEN's House Rating?
- RGEN scores 53 out of 100 (grade C) as of 2026-10-16, ranking #62 of 150 Health Care stocks we cover.
- What do analysts say about RGEN?
- We do not have enough analyst-sentiment data to score this stock.
- When does RGEN report earnings next?
- We do not have a reliable estimate for RGEN's next earnings date (irregular SEC filing history); a rough window is 2026-07-28 to 2027-01-26. Check the company's investor-relations page.
- Is RGEN a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology